Market research
PHVS Pharvaris BV
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 57.7698
- Dividend yield
- Not available
- Beta
- -2.46
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL00150005Y4
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 57.7698
- Dividend yield
- Not available
- Beta
- -2.46
About
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Research context
Pharvaris BV appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PHVS discussion.
5 years, 6 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Pharvaris N.V. Ordinary Shares gets an overall score of 1/5.